Login
ACHIEVE LIFE SCIENCES, INC. logo

ACHIEVE LIFE SCIENCES, INC.

achievelifesciences.com

What Do They Do?

Develops cytisinicline, an investigational medicine for people seeking to quit smoking or vaping.

Who Are Their Customers?

People seeking to quit smoking or vaping are the intended users. The company is considering sales through strategic partners, distributors, a contract sales force or its own sales infrastructure, including possible direct-to-consumer marketing.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +16% (Loss)
vs −$14.4M in Q3 FY2025
  • Oct 1, 2026 CFO Mark Oki stepped down and Benjamin Halladay was appointed The company said Oki's departure was not related to its financial statements or disclosures.
  • May 7, 2026 Thomas King stepped down as board chair; Lucian Iancovici became chair
  • Apr 15, 2026 Andrew Goldberg was appointed CEO and joined the board The appointment took effect following the private placement's closing.

Vaping enters the core program The older report described vaping as an area the company planned to add to its smoking-cessation work; the latest report describes development for both smoking and e-cigarette cessation as part of its nicotine-dependence focus.

Who Do They Compete With?

Competes with Pfizer and GlaxoSmithKline

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support